NO20052491L - Nye vitronektinresepotr antagonistderivater, fremgangsmate til deres fremstilling, anvendelse derav som legemidler og farmasoytiske sammensetninger som inneholder de samme - Google Patents

Nye vitronektinresepotr antagonistderivater, fremgangsmate til deres fremstilling, anvendelse derav som legemidler og farmasoytiske sammensetninger som inneholder de samme

Info

Publication number
NO20052491L
NO20052491L NO20052491A NO20052491A NO20052491L NO 20052491 L NO20052491 L NO 20052491L NO 20052491 A NO20052491 A NO 20052491A NO 20052491 A NO20052491 A NO 20052491A NO 20052491 L NO20052491 L NO 20052491L
Authority
NO
Norway
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
receptor antagonist
drugs
Prior art date
Application number
NO20052491A
Other languages
English (en)
Other versions
NO20052491D0 (no
Inventor
Jean-Marie Ruxer
Jean-Michel Lefrancois
Bertrand Heckmann
Original Assignee
Proskelia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proskelia filed Critical Proskelia
Publication of NO20052491L publication Critical patent/NO20052491L/no
Publication of NO20052491D0 publication Critical patent/NO20052491D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen angår forbindelser med formel (1) hvor R,, R, R, Rog G er som definert i beskrivelsen, fremgangsmåter for deres fremstilling, deres anvendelse som medisiner med en vitronektinreseptorantagonistaktivitet, og farmasøytiske sammensetninger som inneholder forbindelsene.
NO20052491A 2002-11-19 2005-05-23 Nye vitronektinresepotr antagonistderivater, fremgangsmate til deres fremstilling, anvendelse derav som legemidler og farmasoytiske sammensetninger som inneholder de samme NO20052491D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0214429A FR2847254B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
PCT/FR2003/003349 WO2004048375A1 (fr) 2002-11-19 2003-11-12 Nouveaux derives antagonistes du recepteur de la vitronectine leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Publications (2)

Publication Number Publication Date
NO20052491L true NO20052491L (no) 2005-05-23
NO20052491D0 NO20052491D0 (no) 2005-05-23

Family

ID=32187700

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052491A NO20052491D0 (no) 2002-11-19 2005-05-23 Nye vitronektinresepotr antagonistderivater, fremgangsmate til deres fremstilling, anvendelse derav som legemidler og farmasoytiske sammensetninger som inneholder de samme

Country Status (28)

Country Link
US (2) US7582640B2 (no)
EP (2) EP1565467B1 (no)
JP (1) JP4567459B2 (no)
KR (1) KR101140752B1 (no)
CN (2) CN1738817B (no)
AR (2) AR042068A1 (no)
AT (2) ATE431825T1 (no)
AU (2) AU2003299330B2 (no)
BR (1) BR0316307A (no)
CA (1) CA2506310C (no)
CO (1) CO5700761A2 (no)
CY (1) CY1112218T1 (no)
DE (1) DE60327712D1 (no)
DK (2) DK1565467T3 (no)
ES (2) ES2325616T3 (no)
FR (1) FR2847254B1 (no)
HK (2) HK1076277A1 (no)
IL (2) IL168136A (no)
MA (1) MA27492A1 (no)
MX (1) MXPA05005340A (no)
NO (1) NO20052491D0 (no)
PL (1) PL376866A1 (no)
PT (2) PT2070914E (no)
RU (1) RU2412185C2 (no)
SI (2) SI1565467T1 (no)
TW (1) TW200412969A (no)
WO (1) WO2004048375A1 (no)
ZA (1) ZA200502850B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US20110237605A1 (en) * 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
DK3613739T3 (en) 2018-08-17 2020-12-07 Oxurion NV Integrin-antagonister
WO2021165206A1 (en) 2020-02-19 2021-08-26 Oxurion NV Treatment of dry amd with integrin antagonists
WO2022005933A1 (en) 2020-06-29 2022-01-06 Ickovic & Bliss, Inc. Systems, methods, and program products for digital pet identification

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
CA2144762A1 (en) 1992-10-14 1994-04-28 George D. Hartman Fibrinogen receptor antagonists
US5648368A (en) 1992-12-01 1997-07-15 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
EP0762882A4 (en) * 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin Receptor Antagonists
CN1156995A (zh) 1994-06-29 1997-08-13 史密丝克莱恩比彻姆公司 玻璃体结合蛋白受体拮抗剂
JP2000516575A (ja) 1996-06-28 2000-12-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング インテグリンインヒビターとしてのフェニルアラニン誘導体
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6723727B1 (en) * 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
BR9907735A (pt) 1998-01-23 2000-10-17 Aventis Pharma Gmbh Derivados de sulfonamida como inibidores da reabsorção óssea e como inibidores da aderência celular
JP2003504301A (ja) * 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
HUP0103090A3 (en) * 1998-08-07 2002-12-28 Smithkline Beecham Corp Vitronectin receptor antagonist oxazole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
EP1194151A4 (en) 1999-06-23 2003-01-15 Merck & Co Inc ANTAGONISTS OF THE INTEGRIN RECEPTORS
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
KR100712768B1 (ko) * 1999-10-05 2007-05-02 엘리먼트 씩스 (피티와이)리미티드 다이아몬드 클러스터의 성장방법
DE10042655A1 (de) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
FR2847254B1 (fr) * 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine

Also Published As

Publication number Publication date
PT2070914E (pt) 2011-10-12
ES2369561T3 (es) 2011-12-01
ES2325616T3 (es) 2009-09-10
HK1129372A1 (en) 2009-11-27
AR042068A1 (es) 2005-06-08
US20060052398A1 (en) 2006-03-09
KR20050083926A (ko) 2005-08-26
JP4567459B2 (ja) 2010-10-20
EP1565467B1 (fr) 2009-05-20
MA27492A1 (fr) 2005-08-01
US7763621B2 (en) 2010-07-27
US7582640B2 (en) 2009-09-01
CA2506310A1 (fr) 2004-06-10
CO5700761A2 (es) 2006-11-30
HK1076277A1 (en) 2006-01-13
SI2070914T1 (sl) 2012-02-29
US20090149476A1 (en) 2009-06-11
ATE431825T1 (de) 2009-06-15
BR0316307A (pt) 2005-09-27
ATE518842T1 (de) 2011-08-15
AR077476A2 (es) 2011-08-31
RU2412185C2 (ru) 2011-02-20
FR2847254B1 (fr) 2005-01-28
EP2070914B1 (fr) 2011-08-03
DE60327712D1 (de) 2009-07-02
PL376866A1 (pl) 2006-01-09
DK2070914T3 (da) 2011-11-21
CN1738817B (zh) 2011-12-21
CN101928287A (zh) 2010-12-29
RU2005119163A (ru) 2006-02-27
AU2009212779A1 (en) 2009-09-17
CN1738817A (zh) 2006-02-22
AU2003299330A1 (en) 2004-06-18
AU2003299330B2 (en) 2009-09-17
JP2006508999A (ja) 2006-03-16
IL205693A (en) 2011-06-30
CA2506310C (fr) 2014-04-08
EP1565467A1 (fr) 2005-08-24
PT1565467E (pt) 2009-07-15
AU2009212779B2 (en) 2011-09-01
KR101140752B1 (ko) 2012-05-03
NO20052491D0 (no) 2005-05-23
TW200412969A (en) 2004-08-01
IL168136A (en) 2012-06-28
ZA200502850B (en) 2005-10-25
FR2847254A1 (fr) 2004-05-21
EP2070914A1 (fr) 2009-06-17
SI1565467T1 (sl) 2009-10-31
WO2004048375A1 (fr) 2004-06-10
MXPA05005340A (es) 2005-11-17
DK1565467T3 (da) 2009-09-14
CY1112218T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20044826L (no) Pyrrolidinderivater
NO20083434L (no) Benzamid- og heteroarenderivater
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20071504L (no) Pyrimidinderivanter.
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20045486L (no) Nye forbindelser og deres anvendelse
NO20062713L (no) 2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
DE602005007339D1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
NO20062335L (no) Nye diazaspiroalkaner og deres anvendelse i behandlingen av CCR8 medierte sykdommer
TWI262917B (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
DK1537104T3 (da) Azabicycloalkylethere og deres anvendelse som alfa7-nAChR-agonister
NO20085078L (no) Nye forbindelser
NO20072939L (no) Makroloner - aminosubstituerte kinoloner
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
PL378064A1 (pl) Pirymidyny i triazyny hamujące replikację wirusa HIV
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
SE0400284D0 (sv) Novel compounds
NO20062491L (no) Benzoksazinderivter og deres anvendelse
NO20052491L (no) Nye vitronektinresepotr antagonistderivater, fremgangsmate til deres fremstilling, anvendelse derav som legemidler og farmasoytiske sammensetninger som inneholder de samme
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application